Payment overview · 2025
General Payments
$1,763.17
103 reported records · 26 companies
Healthcare provider profile · identity verified
Lisa E Mount, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE RIVER, SC · NPI 1467443606
Verified facts
What the public records show
CMS Open Payments records show Lisa E Mount, MD received $1,763.17 in general payments during 2025 across 103 reported records.
Novo Nordisk Inc accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $209.26 | 11.9% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $201.45 | 11.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.12 | 11.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.01 | 8.8% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.41 | 6.3% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $105.95 | 6.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.27 | 5.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $81.02 | 4.6% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $77.84 | 4.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.24 | 3.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.72 | 3.4% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $55.68 | 3.2% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $48.54 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.94 | 2.4% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $34.39 | 1.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $26.39 | 1.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.99 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.80 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.89 | 1.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.64 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.97 | 1.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.84 | 1.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.56 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.33 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.99 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.93 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,763.17 | 103 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $124.34 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $105.95 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.56 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $94.81 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $81.02 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.43 | 7 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $77.84 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.78 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.78 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.70 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.91 | 13 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.72 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $55.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.00 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.31 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $48.54 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.85 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.90 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.56 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.72 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $34.39 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 256 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
204 | 54 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
256 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 962 | 274 |
| Levothyroxine Sodium | Levothyroxine Sodium | 919 | 234 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 686 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 684 | 186 |
| Omeprazole | Omeprazole | 601 | 178 |
| Gabapentin | Gabapentin | 534 | 164 |
| Losartan Potassium | Losartan Potassium | 498 | 152 |
| Lisinopril | Lisinopril | 470 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 451 | 129 |
| Hydrochlorothiazide | Hydrochlorothiazide | 327 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 312 | 84 |
| Trazodone Hcl | Trazodone Hcl | 299 | 98 |
| Simvastatin | Simvastatin | 293 | 85 |
| Furosemide | Furosemide | 271 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 269 | 79 |
| Eliquis | Apixaban | 256 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 71 |
| Famotidine | Famotidine | 243 | 77 |
| Lorazepam | Lorazepam | 243 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 79 |
| Sertraline Hcl | Sertraline Hcl | 221 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 63 |
| Montelukast Sodium | Montelukast Sodium | 205 | 65 |
| Synthroid | Levothyroxine Sodium | 204 | 54 |
| Tramadol Hcl | Tramadol Hcl | 187 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 88 |
| Metformin Hcl Er | Metformin Hcl | 172 | 57 |
| Meloxicam | Meloxicam | 171 | 62 |
| Telmisartan | Telmisartan | 157 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 41 |
| Metformin Hcl | Metformin Hcl | 148 | 45 |
| Memantine Hcl | Memantine Hcl | 146 | 40 |
| Carvedilol | Carvedilol | 144 | 46 |
| Allopurinol | Allopurinol | 143 | 43 |
| Alprazolam | Alprazolam | 143 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 141 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 44 |
| Buspirone Hcl | Buspirone Hcl | 135 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 118 | 31 |
| Potassium Chloride | Potassium Chloride | 117 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 34 |
| Atenolol | Atenolol | 115 | 30 |
| Celecoxib | Celecoxib | 114 | 41 |
| Mounjaro | Tirzepatide | 113 | 18 |
| Finasteride | Finasteride | 112 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 26 |
| Farxiga | Dapagliflozin Propanediol | 109 | 32 |
| Valsartan | Valsartan | 109 | 27 |
| Irbesartan | Irbesartan | 108 | 29 |
| Glipizide Er | Glipizide | 102 | 29 |
| Mirtazapine | Mirtazapine | 98 | 31 |
| Estradiol | Estradiol | 95 | 41 |
| Ezetimibe | Ezetimibe | 92 | 27 |
| Donepezil Hcl | Donepezil Hcl | 87 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 28 |
| Clonazepam | Clonazepam | 79 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 13 |
| Benazepril Hcl | Benazepril Hcl | 72 | 16 |
| Gemtesa | Vibegron | 71 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 25 |
| Spironolactone | Spironolactone | 67 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 16 |
| Azithromycin | Azithromycin | 54 | 52 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 39 |
| Warfarin Sodium | Warfarin Sodium | 50 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 48 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 21 |
| Glimepiride | Glimepiride | 46 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 17 |
| Lovastatin | Lovastatin | 46 | 14 |
| Cefuroxime | Cefuroxime Axetil | 45 | 42 |
| Glipizide | Glipizide | 45 | 15 |
| Prednisone | Prednisone | 45 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 35 |
| Ketoconazole | Ketoconazole | 43 | 26 |
| Propranolol Hcl | Propranolol Hcl | 40 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 21 |
| Bupropion Xl | Bupropion Hcl | 38 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Ibuprofen | Ibuprofen | 38 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Ozempic | Semaglutide | 37 | 11 |
| Fluconazole | Fluconazole | 36 | 21 |
| Hydrocortisone | Hydrocortisone | 36 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 17 |
| Xarelto | Rivaroxaban | 34 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 24 |
| Amoxicillin | Amoxicillin | 30 | 26 |
| Cephalexin | Cephalexin | 30 | 27 |
| Topiramate | Topiramate | 30 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | 11 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 26 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 20 |
| Nystatin | Nystatin | 22 | 14 |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 14 |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 11 |
| Erythromycin | Erythromycin Base | 19 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Repaglinide | Repaglinide | 17 | suppressed |
| Euthyrox | Levothyroxine Sodium | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,763.17 · 103 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GVOKE HYPOPEN, INJECTAFER, INSPIRE, KISUNLA, Korlym, LEQVIO, MOUNJARO, NEFFY, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error